DasaHIT Trial: Weekend Dasatinib Breaks Maintain Molecular Response in Chronic Myeloid Leukemia

DasaHIT Trial: Weekend Dasatinib Breaks Maintain Molecular Response in Chronic Myeloid Leukemia

Dasatinib taken five days a week kept major molecular response (MMR) noninferior to continuous daily dosing in chronic-phase chronic myeloid leukemia (CML) in the phase III DasaHIT trial (JCO, 2026). At 24 months, MMR rates were 78% with weekend breaks and 81% with continuous treatment. The intermittent schedule did not lower the cumulative toxicity score, the trial’s second coprimary endpoint. It was associated with fewer pleural and pericardial effusions and better quality of life, mainly in first-line patients.

Why Test a Weekend Break

BCR::ABL1 tyrosine kinase inhibitors have made CML mortality low for most patients, so long-term tolerability now matters as much as response. Continuous kinase inhibition can cause chronic adverse effects that impair daily functioning even when disease control is adequate.

Dasatinib has a short plasma half-life of three to five hours, and tyrosine phosphorylation can reactivate within six to eight hours of a dose. Brief kinase inhibition nevertheless induces apoptosis in BCR::ABL1-positive cells, which suggests that continuous target inhibition may not be necessary. Pleural effusions affected about 20% of patients in the first two years in earlier studies, and toxicity often forces dose reductions or interruptions. A preliminary study of 33 patients found that weekday dosing with two-day weekend breaks could reduce effusion severity and hematologic toxicity, which led to DasaHIT.

Trial Design: 29% Less Weekly Exposure at the Same Daily Dose

DasaHIT was an open-label, multicenter trial across 52 hospitals and practices in Germany, run by the German CML Alliance. It randomized 289 patients with chronic-phase CML, either newly diagnosed or needing second-line or later treatment for intolerance or resistance, to dasatinib 100 mg daily (n = 147) or 100 mg on weekdays only (n = 142). The intermittent arm cut planned weekly exposure from 700 mg to 500 mg, about 29%, with no change in the dose on treatment days.

Most patients (232, 80%) received dasatinib first line, split equally between arms; 57 received it in a later line. Median age was 54 years, and 59% were male. The coprimary endpoints were:

  • MMR at 24 months: BCR::ABL1 transcripts of 0.1% or lower on the International Scale, with a noninferiority margin of 15 percentage points.
  • Cumulative toxicity over 24 months: a score based on the maximum severity of 18 clinically relevant dasatinib-associated adverse events of grade 2 or higher. Molecular monitoring took place every three months.

Molecular Response: Noninferior Overall, Uncertain in Later Lines

Among 260 patients with 24-month molecular data (130 per arm):

MMR: 81% with continuous dasatinib vs 78% with intermittent dosing. The 90% confidence interval for the difference ran from 5 points favoring intermittent to 11 points favoring continuous treatment, below the 15-point margin .
Time to response: no significant differences for MMR, MR4, or MR4.5.

In an exploratory subgroup of 206 evaluable first-line patients, MMR was 79% with continuous and 81% with intermittent dosing, which met the noninferiority criterion. The strongest evidence for weekend breaks therefore applies to first-line treatment.

Later-line results differed: MMR was 87% with continuous and 62.5% with intermittent dosing (P = 0.039), a gap that missed the noninferiority criterion. The intermittent later-line group was older (median age 61 vs 53 years), and in multivariable analysis older age was independently associated with failure to reach MMR while treatment assignment was no longer significant.

DasaHIT Trial: Weekend Dasatinib Breaks Maintain Molecular Response in Chronic Myeloid Leukemia

Toxicity: Similar Cumulative Scores, Fewer Effusions

Safety data through 24 months were evaluable in 255 patients. The overall toxicity burden did not differ:

  • Grade 2-4 adverse events in the toxicity endpoint: 58% with continuous vs 56% with intermittent dosing.
  • Median cumulative toxicity score: 2 in both arms.
  • 24-month cumulative incidence of a first grade 2-4 event: 55% vs 54%.

The trial therefore did not show superiority on cumulative toxicity. The score pooled hematologic, fluid retention, pulmonary, gastrointestinal, skin, and musculoskeletal events, so differences in individual toxicities could be diluted.

Exploratory analyses did find a difference in serosal effusions. Pleural or pericardial effusions occurred in 21 of 130 patients (16%) on continuous dasatinib and 10 of 125 (8%) on intermittent dosing. A post hoc competing-risk analysis gave 24-month cumulative incidences of 16% vs 7%. The finding fits earlier observations that dasatinib serosal toxicity depends on exposure, but it was not the prespecified safety test.

Discontinuation for toxicity occurred in 16% of the continuous arm and 10% of the intermittent arm, and for treatment failure in 6% and 10%. Overall cumulative discontinuation did not differ significantly.

Quality of Life Favored Weekend Breaks in 1L Patients

Health-related quality of life was assessed in 217 patients with European Organisation for Research and Treatment of Cancer questionnaires plus CML-specific and fatigue instruments, with a change of at least ten points from baseline considered clinically meaningful. Outcomes generally favored intermittent dosing, most consistently in first-line patients. Women appeared to benefit more. Later-line patients had less favorable trajectories. Incomplete questionnaire data were not imputed, and the subgroup comparisons were exploratory.

Progression and Survival

After a median follow-up of 43 months, no patient in either arm had progressed to accelerated or blast phase, and no CML-related deaths occurred. Eight deaths from unrelated causes were recorded, six in the intermittent arm and two in the continuous arm. Five-year overall survival was 99% with continuous and 95% with intermittent dosing. The trial was not powered to establish equivalence for long-term survival or rare progression events.

Weekend Breaks vs 50 mg Daily

DasaHIT is the first randomized test of reduced dasatinib exposure. Until now, dose optimization rested on nonrandomized data for continuous 50 mg daily and on guideline-endorsed dose reduction for intolerance. DasaHIT keeps 100 mg on treatment days and stops completely for two days. First-line patients held their molecular response, and an accompanying Journal of Clinical Oncology editorial suggested that intermittent dasatinib could become a new standard of care in chronic-phase CML.

The evidence is strongest in newly diagnosed patients. The prespecified toxicity endpoint showed no superiority, later-line results are uncertain. DasaHIT did not test weekend breaks in higher-risk disease, and it does not show whether they preserve the sustained deep molecular responses that treatment-free remission requires.

Source: La Rosée P, Ernst P, Fabisch C, et al. Dasatinib Dose Optimization With Weekend Drug Holiday for Improved Tolerability in Chronic Myeloid Leukemia (DasaHIT): A German Chronic Myeloid Leukemia Alliance Randomized Trial. Journal of Clinical Oncology. 2026. DOI: 10.1200/JCO-26-00899.

OncoDaily TV

Sona Karamyan
Fact checked by Sona Karamyan MD, Medical Oncologist
Amalya Sargsyan
Medically reviewed by Amalya Sargsyan MD, Medical Oncologist